Abstract
Pityriasis lichenoides et varioliformis acuta (PLEVA) is an uncommon inflammatory skin disease. Generally, it is a self-healing process that resolves in a few months but, sometimes, may evolve into pityriasis lichenoides chronica. Cutaneous manifestation may vary from cases with mild presentation to forms with multiple ulcero-necrotic lesions associated to systemic symptoms. Generally, treatment is not necessary in the mild form. If the patient presents fever, an antibiotic treatment is recommended. Erythromycin is the antibiotic of choice in children, while tetracycline is preferable in adults. Cases with moderate cutaneous lesions, in the absence of fever, could be treated with topical corticosteroids and phototherapy. In adults, NB UVB or PUVA may be preferable. In more severe forms, usually associated to systemic symptoms, in addition to an oral antibiotic, it could be appropriate to prescribe a systemic steroid or methotrexate.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Aydogan K, Saricaoglu H, Turan H. Narrowband UVB (311 nm, TL01) phototherapy for pityriasis lichenoides. Photodermatol Photoimmunol Photomed. 2008;24:128–33.
Bellinato F, Maurelli M, Gisondi P, Girolomoni G. A systematic review of treatments for Pityriasis Lichenoides. J Eur Acad Dermatol Venereol. 2019;33:2039–49.
Boralevi F, Cotto E, Baysse L, et al. Is varicella-zoster virus involved in the etiopathogeny of pityriasis lichenoides? J Invest Dermatol. 2003;121:647–8.
Borra T, Custrin A, Saggini A, et al. Pityriasis lichenoides, atypical pityriasis lichenoides, and related conditions: a study of 66 cases. Am J Surg Pathol. 2018;42:1101–12.
Calzavara Pinton PC, Capezzera R, Zane C, et al. Medium-dose ultraviolet al therapy for pityriasis lichenoides et varioliformis acuta and pityriasis lichenoides chronica. J Am Acad Dermatol. 2002;47:410–4.
Cornelison RL, Knox JM, Everett MA. Methotrexate for the treatment of Mucha-Habermann disease. Arch Dermatol. 1972;106:507–8.
Ersoy-Evans S, Greco MF, Mancini AJ, Subaşi N, Paller AS. Pityriasis lichenoides in childhood: a retrospective review of 124 patients. J Am Acad Dermatol. 2007;56:205–10.
Gelmetti C, Rigoni C, Alessi E, et al. Pityriasis lichenoides in children: a long-term follow-up of eighty-nine cases. J Am Acad Dermatol. 1990;23:473–8.
Gritiyarangsan P, Pruenglampoo S, Ruangratanarote P. Comparative studies of treatments for pityriasis lichenoides. J Dermatol. 1987;14:258–61.
Hapa A, Ersoy-Evans S, Karaduman A. Childhood pityriasis lichenoides and oral erythromycin. Pediatr Dermatol. 2012;29:719–24.
Lis-Swiezty A, Michalska-Bankowska A, Zielonka-Kucharzewska A, et al. Successful therapy of cyclosporin A in pityriasis lichenoides et varioliformis acuta preceded by hand, foot and mouth disease. Antivir Ther. 2016;21:273–5.
Ogrum A, Takci Z, Seckin HY, et al. A case of pityriasis lichenoides: rapid resolution with azithromycin monotherapy in 3 weeks. Dermatol Ther. 2018;31:e12681.
Pavlotsky F, Baum S, Barzilai A, et al. UVB therapy of pityriasis lichenoides – our experience with 29 patients. J Eur Acad Dermatol Venereol. 2006;20:542–7.
Piamphongsant T. Tetracycline for the treatment of pityriasis lichenoides. Br J Dermatol. 1974;91:319–22.
Powell FC, Muller SA. Psoralens and ultraviolet A therapy of pityriasis lichenoides. J Am Acad Dermatol. 1984;10:59–64.
Sauer GC. Pentoxifylline (Trental) therapy for vasculitis of pityriasis lichenoides et varioliformis. Arch Dermatol. 1985;121:1487.
Tay YK, Morelli JG, Weston WL. Experience with UVB phototherapy in children. Pediatr Dermatol. 1996;13:406–9.
Truhan AP, Hebert AA, Esterly NB. Pityriasis lichenoides in children: therapeutic response to erythromycin. J Am Acad Dermatol. 1986;15:66–70.
Zlatkov NB, Andreev VC. Toxoplasmosis and pityriasis lichenoides. Br J Dermatol. 1972;87:114–6.
Further Reading
Bowers S, Warshaw EM. Pityriasis lichenoides and its subtypes. J Am Acad Dermatol. 2006;55:557–72.
Farnaghi F, Seirafi H, Ehsani AH, Agdari ME, Noormohammadpour P. Comparison of the therapeutic effects of narrow band UVB vs. PUVA in patients with pityriasis lichenoides. J Eur Acad Dermatol Venereol. 2011;25:913–6.
Fernandes NF, Rozdeba PJ, Schwartz RA, Kihiczak G, Lambert WC. Pityriasis lichenoides et varioliformis: a disease spectrum. Int J Dermatol. 2010;49:257–61.
Geller L, Antonov NK, Lauren CT, Morel KD, Garzon MC. Pityriasis lichenoides in childhood: review of clinical presentation and treatment options. Pediatr Dermatol. 2015;32:579–92.
Horie C, Mizukawa Y, Yamazaki Y, Shiohara T. Varicella zoster virus as a possible trigger for the development of pityriasis lichenoides et varioliformis acuta: retrospective analysis of our institutional cases. Clin Exp Dermatol. 2018;43:703–7.
Ito N, Ohshima A, Hashizume H, Takigawa M, Tokura Y. Febrile ulceronecrotic Mucha-Habermann’s disease managed with methylprednisolone semipulse and subsequent methotrexate therapies. J Am Acad Dermatol. 2003;49:1142–8.
Jung F, Sibbald C, Bohdanowicz M, Ingram JR, Piguet V. Systematic review of efficacies and adverse effects of treatments for pityriasis lichenoides. Br J Dermatol. 2020;183(6):1026–32. https://doi.org/10.1111/bjd.18977.
Karouni M, Abou Rahal J, Kurban M, Kibbi AG, Abbas O. Possible role of plasmacytoid dendritic cells in pityriasis lichenoides. Clin Exp Dermatol. 2018;43:404–9.
Kaufman WS, McNamara EK, Curtis AR, et al. Febrile ulceronecrotic Mucha-Habermann disease (pityriasis lichenoides et varioliformis acuta fulminans) presenting as Stevens-Johnson syndrome. Pediatr Dermatol. 2012;29:135–40.
Khachemoune A, Blyumin ML. Pityriasis lichenoides: pathophysiology, classification, and treatment. Am J Clin Dermatol. 2007;8:29–36.
Kempf W, Pfaltz K, Vermeer MH, et al. EORTC, ISCL, and USCLC consensus recommendations for the treatment of primary cutaneous CD30-positive lymphoproliferative disorders: lymphomatoid papulosis and primary cutaneous anaplastic large-cell lymphoma. Blood. 2011;118:4024–35.
Kempf W, Kazakov DV, Palmedo G, et al. Pityriasis lichenoides et varioliformis acuta with numerous CD30(+) cells: a variant mimicking lymphomatoid papulosis and other cutaneous lymphomas. A clinicopathologic, immunohistochemical, and molecular biological study of 13 cases. Am J Surg Pathol. 2012;36:1021–9.
Kim HS, Yu DS, Kim JW. A case of febrile ulceronecrotic Mucha-Habermann’s disease successfully treated with oral cyclosporin. J Eur Acad Dermatol Venereol. 2007;21:272–3.
Macias VC, Marques-Pinto G, Cardoso J. Phototherapy for pityriasis lichenoides: our experience. Cutan Ocul Toxicol. 2013;32:124–7.
Marenco F, Fava P, Fierro MT, Quaglino P, Bernengo MG. High-dose immunoglobulins and extracorporeal photochemotherapy in the treatment of febrile ulceronecrotic Mucha-Habermann disease. Dermatol Ther. 2010;23:419–22.
Menzinger S, Frassati-Biaggi A, Leclerc-Mercier S, Bodemer C, Molina TJ, Fraitag S. Pityriasis lichenoides: a large histopathological case series with a focus on adnexotropism. Am J Dermatopathol. 2020;42:1–10.
Miyamoto T, Takayama N, Kitada S, Hagari Y, Mihara M. Febrile ulceronecrotic Mucha-Habermann disease: a case report and a review of the literature. J Clin Pathol. 2003;56:795–7.
Romani J, Puig L, Fernandez-Figueras MT, de Moragas JM. Pityriasis lichenoides in children: clinicopathologic review of 22 patients. Pediatr Dermatol. 1998;15:1–6.
Zaaroura H, Sahar D, Bick T, Bergman R. Relationship between pityriasis lichenoides and mycosis fungoides: a clinicopathological, immunohistochemical, and molecular study. Am J Dermatopathol. 2018;40:409–15.
Zang JB, Coates SJ, Huang J, Vonderheid EC, Cohen BA. Pityriasis lichenoides: long-term follow-up study. Pediatr Dermatol. 2018;35:213–9.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2023 Springer Nature Switzerland AG
About this chapter
Cite this chapter
Fania, L., Didona, B. (2023). Pityriasis Lichenoides Acuta. In: Katsambas, A.D., Lotti, T.M., Dessinioti, C., D'Erme, A.M. (eds) European Handbook of Dermatological Treatments. Springer, Cham. https://doi.org/10.1007/978-3-031-15130-9_71
Download citation
DOI: https://doi.org/10.1007/978-3-031-15130-9_71
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-031-15129-3
Online ISBN: 978-3-031-15130-9
eBook Packages: MedicineMedicine (R0)